Metformin lowers EDSD rates by nearly half, says Johns Hopkins University
Metformins are a class of drugs that help treat and prevent erectile problems, but a new study has shown that they are also able to help prevent or reduce erectile symptoms.
In fact, the drug has been shown to lower EDSDs rates by a third or more.
Jennifer F. Smith of Johns Hopkins School of Medicine and colleagues compared EDS rates for men taking MetformIN to those for men who were on oral contraceptives, which are also known as pill, patch, or implant medications.
They found that while EDS is a common symptom, men taking the drug had significantly lower rates of erectile difficulties, and the drugs were equally effective at treating EDS in both men and women.
“We were really impressed with the efficacy of the drugs and their ability to reduce EDS,” said Dr. Smith, who was not involved in the study.
The researchers are now investigating whether the drugs can also reduce symptoms of other types of erections, such as erectile dysfunctions, which can be caused by some medications.
MetformIn, also known by its brand name metformen, is an oral medication used to treat erectile disorders such as dry mouth, constipation, and bloating.
Metforms are prescribed for erectile health problems in more than 40 countries, including the United States.
In addition to lowering EDS symptoms, MetformIns are often used to lower blood pressure and blood sugar levels, as well as to treat depression.
Erectile dysfunction is a condition that affects about 1 in 20 men in the United Kingdom.
Many people with EDS have difficulty maintaining their erection and have difficulty performing certain tasks, including sexual intercourse.
They also experience a range of other side effects, including pain, difficulty achieving an erection, difficulty getting an erection or a drop in sex drive.
“The drugs we are currently evaluating may be able to provide relief to some of these other symptoms and reduce the risk of erectilatory dysfunction,” Dr. M. K. Singh, the study’s senior author, said in a press release.
“This could be a potential avenue for potential therapy.”
For the study, Dr. Singh and her colleagues recruited a large cohort of men, most of whom had been taking oral contraceptives for at least 10 years.
They enrolled them in the MetformINS Study and asked them to take two tablets of metformins and an oral contraceptive every day for about two weeks.
After the men were done taking the drugs, the researchers assessed their EDS, which is an indication of erectility, in a computer-assisted diagnostic imaging system.
They then compared their EDD rates to those of men who did not take the drugs.
For every pill taken, they also collected blood samples, including levels of the protein that makes up the blood vessels in the penis.
The investigators then looked at how the metformines affected these changes in the blood.
The men were more likely to be having EDS if they were taking the metforms than if they had been on oral contraceptive.
“Our study found that men taking metformIns had significantly higher rates of EDS and higher levels of testosterone compared to men taking other oral contraceptive drugs,” Dr Smith said.
“Metformins may therefore help to lower erectile functioning.”
The researchers hope to do more studies on how metformens work to see if the drugs reduce the effects of other erectile diseases, such of diabetes or heart disease.
A similar study of metforms from the U.S. is also underway, and they plan to do some more research to see whether they can also be effective for EDS.
“It is possible that metformers could be more effective in treating ESD than oral contraceptives,” Dr Singh said.
In the meantime, the Metforms study showed that, while oral contraceptives can help reduce EEDs, the drugs also have side effects that can cause serious side effects.
For instance, the metabolin-containing drug metformans are also linked to the development of heart defects in men.
“There is still much work to be done in this area to determine whether these drugs are safe and effective in people with ED,” Dr F. S. Smith said in the press release, adding that further studies are needed to determine if the drug can reduce EUD symptoms.